Literature DB >> 6271870

Impaired regulation of Epstein-Barr virus-induced lymphocyte proliferation in rheumatoid arthritis is due to a T cell defect.

J M Depper, H G Bluestein, N J Zvaifler.   

Abstract

The rate of outgrowth of EBV-infected B lymphocytes is regulated by normal T lymphocytes. Removal of T cells from normal whole lymphoid populations (PBM) markedly shortens the outgrowth time of the remaining B lymphocytes. There is little difference in the much more rapid outgrowth of rheumatoid PBM after the removal of T cells, which suggests that RA lymphoid cells are unable to regulate this process. To determine whether RA T cells are defective, or EBV-infected RA B cells are unresponsive to regulatory signals, EBV-induced outgrowth in autologous and allogeneic mixtures of RA and normal B and T cells was evaluated, employing morphologic criteria and 3H-thymidine incorporation. The difference in outgrowth between RA and normal PBM was reproduced by reconstitution of EBV-infected B cells with mitomycin-treated autologous T cells. In cell-mixing experiments, normal T cells appropriately regulated both normal and RA B cells similarly, whereas RA T cells were defective in regulating either B cell population. Thus, the rapid outgrowth of EBV-infected rheumatoid lymphoid cells is due to defective T cell regulation. Moreover, normal regulation does not require cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6271870

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  Non-Hodgkin's lymphoma in rheumatoid arthritis.

Authors:  D Porter; R Madhok; H Capell
Journal:  Ann Rheum Dis       Date:  1991-05       Impact factor: 19.103

2.  Immunohistochemical demonstration of CD23 expression on lymphocytes in rheumatoid synovitis.

Authors:  E A Hellen; D C Rowlands; T T Hansel; G D Kitas; J Crocker
Journal:  J Clin Pathol       Date:  1991-04       Impact factor: 3.411

3.  Epstein-Barr virus serologic abnormalities and risk of rheumatoid arthritis among women.

Authors:  Barbara L Goldstein; Lori B Chibnik; Elizabeth W Karlson; Karen H Costenbader
Journal:  Autoimmunity       Date:  2011-10-20       Impact factor: 2.815

4.  Spontaneous establishment of an Epstein-Barr virus-infected fibroblast line from the synovial tissue of a rheumatoid arthritis patient.

Authors:  J Koide; K Takada; M Sugiura; H Sekine; T Ito; K Saito; S Mori; T Takeuchi; S Uchida; T Abe
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

5.  Evidence for oligoclonal B cell expansion in the peripheral blood of patients with rheumatoid arthritis.

Authors:  D A Fox; B R Smith
Journal:  Ann Rheum Dis       Date:  1986-12       Impact factor: 19.103

6.  Comparison of the immune response to Epstein-Barr virus and cytomegalovirus in sera and synovial fluids of patients with rheumatoid arthritis.

Authors:  M Musiani; M Zerbini; S Ferri; M Plazzi; G Gentilomi; M La Placa
Journal:  Ann Rheum Dis       Date:  1987-11       Impact factor: 19.103

7.  Rheumatoid arthritis synovial membrane contains a 62,000-molecular-weight protein that shares an antigenic epitope with the Epstein-Barr virus-encoded associated nuclear antigen.

Authors:  R Fox; R Sportsman; G Rhodes; J Luka; G Pearson; J Vaughan
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

8.  HLA-DR genotype risks in seropositive rheumatoid arthritis.

Authors:  L Legrand; G M Lathrop; A Marcelli-Barge; A Dryll; T Bardin; N Debeyre; J C Poirier; M Schmid; A Ryckewaert; J Dausset
Journal:  Am J Hum Genet       Date:  1984-05       Impact factor: 11.025

9.  Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis.

Authors:  G Tosato; A D Steinberg; R Yarchoan; C A Heilman; S E Pike; V De Seau; R M Blaese
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

10.  Correlative studies of rheumatoid factors and anti-viral antibodies in patients with rheumatoid arthritis.

Authors:  A S Ferraro; M M Newkirk
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.